Shots:

• The company initiates the registrational clinical trials to evaluate the biosimilarity of BSC1020 vs Neupogen in patients with cancer. The trial is expected to complete in July 2022
• Neupogen has been manufactured at Amgen's Biologics facility in Puerto Rico while the trial is designed to identify the similarity b/w biosimilar and Neupogen
• The company has entered into a manufacturing and operations agreement with OcyonBio & has plans to complete a technology transfer to initiate manufacturing in Puerto Rico in 2022. The company will use its multiple assets for the research, development, and manufacture of biosimilar therapies

Ref: Globe Newswire | Image: OcyonBio